Vion Pharmaceuticals, Inc.

Vion Pharmaceuticals, Inc.
Vion Pharmaceuticals, Inc.
Former type Public OTC BB: VIONQ.OB)
Industry Pharmaceuticals
Founded 1992
Defunct 2009
Headquarters New Haven, Connecticut, United States

Vion Pharmaceuticals, Inc. was a New Haven, Connecticut based pharmaceutical company founded in March 1992 to commercialize several discoveries made in the biomedical laboratories at Yale University. The company filed for bankruptcy on Dec. 17, 2009 after the U.S. FDA announced that the drug developer’s application for the Onrigin anti-cancer injection would not be approved in the filed form.

Clinical Development

Two anticancer agents, Onrigin (laromustine), formerly Cloretazine (VNP40101M), and Triapine, are in human clinical trials. Onrigin (laromustine), a novel alkylating agent, is being evaluated in a Phase 2 trial in elderly de novo poor-risk AML. In addition, four trials of Onrigin (laromustine) are underway in (i) elderly AML and myelodysplastic syndrome (MDS) in combination with cytarabine; (ii) AML and MDS in combination with standard remission-induction therapy; (iii) brain tumors in combination with temozolomide; and (iv) advanced hematologic malignancies in combination with hematopoietic cell transplantation. Triapine, a ribonucleotide reductase inhibitor, is being evaluated in clinical trials sponsored by the National Cancer Institute.

External links